Fast Growing ASX Stocks Where Insider Buying Meets Big Growth Plans

Global inflation signals, diverging central bank paths and higher government bond yields are putting more pressure on company fundamentals. Investors are paying closer attention to businesses where management is financially committed and growth expectations remain optimistic. That is exactly what the Fast Growing Stocks With High Insider Ownership screener is designed to highlight. It filters for companies where insiders have meaningful skin in the game and where analysts and management both indicate solid growth potential. This article walks through three of the most notable stocks from that screener to help you focus your research on opportunities with aligned incentives and clear growth ambitions.

Predictive Discovery (ASX:PDI)

Overview: Predictive Discovery is an Australian gold company focused on exploring, developing and operating gold projects in West Africa, anchored by its flagship 356 square kilometre Bankan Gold project in north east Guinea and supported by the producing Kiniero and Nampala mines.

Market Cap: A$3.3b

Predictive Discovery provides leveraged exposure to West African gold, with two operating mines already generating cash to support the large Bankan project, a 9.5 million ounce resource and 4.5 million ounces in reserves. Analysts note that current operations are still loss making and the company has less than one year of cash runway. High forecast returns on equity sit beside heavy insider selling, recent shareholder dilution and a very rich P/B multiple. This makes it a stock where the potential outcomes depend heavily on project execution, funding access and how investors weigh those trade offs.

High insider ownership, loss making operations and a rich P/B mean Predictive Discovery is not a simple story. Get the full picture with the 2 key rewards and 4 important warning signs (2 are major!)

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals is a commercial stage radiopharmaceutical company that develops and sells targeted imaging and treatment products for cancers such as prostate, kidney and brain tumours, aiming to help doctors both find and treat tumours using the same underlying technology.

Operations: Telix generates most of its US$804.3m revenue from Precision Medicine at about US$621.9m, alongside Manufacturing Solutions at US$245.1m and Therapeutics at US$9.3m, with the United States contributing about US$784.9m of total sales.

Market Cap: A$4.8b

Telix Pharmaceuticals has already built a global commercial footing with Illuccix and Gozellix, while using acquisitions to bring more manufacturing and distribution in house, which can support both margins and supply reliability over time. At the same time, it is still loss making, funding intensive R&D and manufacturing buildout, and facing an SEC subpoena and clear pricing pressure in prostate cancer imaging. The real swing factor is a broad late stage pipeline in prostate, kidney and brain cancers, where several major trials and regulatory decisions sit ahead. With the stock having already repriced after a sharp share price fall, the gap between strong growth expectations and these risks is exactly what investors need to weigh up next.

Telix Pharmaceuticals pairs fast building revenue with a late stage pipeline that could reshape its profile, yet the real story sits in the analyst forecasts for Telix Pharmaceuticals and what they suggest about one underappreciated risk.

Lindian Resources (ASX:LIN)

Overview: Lindian Resources is a Perth based explorer focused on rare earths, bauxite and gold projects in Africa, with its flagship Kangankunde Rare Earths project in Malawi positioned as the core asset alongside a growing regional footprint that includes Tanzania, Guinea and a new commercial hub in Singapore.

Market Cap: A$1.4b

Lindian Resources sits at the intersection of very high growth expectations and real execution risk. Kangankunde is being pushed toward first rare earth concentrate in Q4 2026, backed by a potential downstream processing route through the SARECO facility in Kazakhstan and a new Singapore office to handle marketing and logistics. At the same time, revenue is currently minimal, the business is loss making with earnings declining in recent years, and shareholders have already faced heavy dilution and higher risk borrowing. An inexperienced, non independent board adds another layer of governance risk. For investors who want exposure to a rare earth development story shaped by insider commitment and aggressive growth forecasts, the key question is how these trade offs stack up against the opportunity.

Growth expectations around Kangankunde are accelerating while governance and funding questions still hang over Lindian Resources. Before you decide how that trade off stacks up, read the analyst forecasts for Lindian Resources

The three stocks in this article are only a starting point, and the full screener has surfaced 98 more companies with equally compelling growth and insider ownership stories in the Fast Growing Stocks With High Insider Ownership screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on your highest conviction ideas.

Take Control of Your Investment Journey

If Telix Pharmaceuticals or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Markets move fast and the cleanest breakout ideas rarely stay under the radar for long. Review these fresh picks before the crowd, while the data still matters, and consider your options promptly.

• Target potential income while prices are still settling by scanning a curated group of high yield opportunities in the 4 dividend fortresses.
• Explore early momentum in companies involved in AI infrastructure by reviewing the hand picked 55 AI infrastructure stocks.
• Look for under the radar quality as it builds quiet momentum across the curated 11 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com